Aurora Cannabis vs. Canopy Growth: Which Stock is a Better Buy?

: ACB | Aurora Cannabis Inc. News, Ratings, and Charts

ACB – The cannabis industry has witnessed surging demand amid the pandemic-driven lockdown and legalization in various states. With loosening regulation in the United States if Biden is elected, Aurora Cannabis (ACB) and Canopy Growth (CGC) should grow exponentially in the upcoming months. But which stock is the better buy now? Let’s take a look.

Aurora Cannabis Inc. (ACB) and Canopy Growth Corporation (CGC) are two leading cannabis producers. While ACB manufactures cannabis through horizontally and vertically integrated value chain production, CGC develops cannabis for both medical and recreational uses through two segments – Cannabis Hemp and other Consumer products.

Both companies have generated significant returns over the past five years. While ACB gained 28.7% over this period, CGC returned 1081.2%. In terms of six-month price performance, CGC is the clear winner with 29.6% gains versus ACB negative returns.

But which stock is the better buy now? Let’s find out.

Latest Movements

On October 1st, CGC partnered with Acreage Holdings, Inc. to distribute its select THC beverage collection across the United States in summer 2021. CGC entered into a collaborative agreement with Martha Stewart and Marquee Brands to launch a new line of hemp-derived wellness supplements under Martha CBD. Additionally, CGC announced the opening of 10 new retail stores across Canada in August.

ACB is currently in the process of reducing costs through layoffs and shut down of unprofitable product lines. It is reportedly aiming to develop high-cost projects through external contractors to reduce overhead expenses for the next two quarters. This should allow the company to generate substantial profits from operations.

Recent Financial Results

CGC’s net revenue grew 22% year-over-year to C$110 million in the fiscal first quarter ended June 2020. Gross margin increased 1,300 basis points sequentially to 7%. CGC ended the quarter with C$2 billion in cash and short-term investments.

ACB’s adjusted gross margin on consumer and medical cannabis revenue increased 600 basis points and 700 basis points, respectively, in the fiscal fourth quarter ended June 2020. Medical cannabis revenue grew 4% from the previous quarter to $32.20 million. The company had $162.18 million in cash as of June 30th.

Past and Expected Financial Performance

ACB’s revenue and total assets increased at a CAGR of 149% and 105.1%, respectively, over the past three years. Analysts expect EPS and revenue to grow 96.4% and 12.7%, respectively, in 2021.

CGC’s revenue and total assets increased at a CAGR of 104.7% and 109.6%, respectively, over the past three years. Analysts expect EPS and revenue to rise 27.1% and 21.6%, respectively, in 2021.


CGC’s revenue is 1.50 times what ACB generates. CGC is also more profitable as well with a gross margin of 22.8%, compared to ACB’s negative values.


In terms of trailing 12-month price/sales, CGC is currently trading at 22.25x, 817.6% more expensive than ACB, which is currently trading at 2.29x. CGC’s EV/ sales of 20.64x is 121.6% more expensive than ACB’s 4.12x.

CGC is also more expensive than ACB in terms of trailing 12-month price to book ratio (1.98x versus 0.35x).

Thus, ACB is the more affordable stock.

POWR Ratings

While CGC is rated “Neutral” in our proprietary POWR Ratings system, ACB is rated “Strong Sell”. Here’s how the four components of overall POWR Rating are graded for both these stocks:

CGC holds a “B” for Trade Grade, Peer Grade, and Industry Rank, and “C” in Buy & Hold Grade. In the 240-stock Medical-Pharmaceuticals industry, it is currently ranked #120.

ACB has an “B” for Industry Rank, “D” for Peer Grade, and “F” for Trade Grade and Buy & Hold Grade. It is ranked #131 in the same industry.

The Winner

With increasing demand for medical cannabis across the world and talks regarding legalization of marijuana in the United States if Biden becomes the next president, ACB and CGC have significant upside left. However, CGC has an edge over ACB as it manufactures cannabis for recreational usage as well, unlike ACB which sticks to medical needs. CGC’s promising growth over the past three years, favorable revenue and EPS growth outlook and higher profit margin make it a better investment option despite a premium valuation.

Want More Great Investing Ideas?

Top 11 Picks for Today’s Market

Dangerous Outlook for Stocks Into Election

5 WINNING Stocks Chart Patterns

ACB shares were trading at $4.77 per share on Thursday afternoon, down $0.08 (-1.65%). Year-to-date, ACB has declined -81.60%, versus a 8.47% rise in the benchmark S&P 500 index during the same period.

About the Author: Aditi Ganguly

Aditi is an experienced content developer and financial writer who is passionate about helping investors understand the do’s and don'ts of investing. She has a keen interest in the stock market and has a fundamental approach when analyzing equities. More...

More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
ACBGet RatingGet RatingGet Rating
CGCGet RatingGet RatingGet Rating

Most Popular Stories on

:  |  News, Ratings, and Charts

3 Signs of a NEW Stock Market Bubble

Value investors are pounding the table that the stock market (SPY) is already in bubble territory not unlike 1999. Indeed they are right about the lofty valuation levels. But they are wrong that it’s time to get ready for the next bear market to emerge. Check out Steve Reitmeister's game plan to ride the bubble up and then parachute out at the right time. Read on for more...

:  |  News, Ratings, and Charts

Top 10 Value Stocks

The S&P 500 (SPY) has shown mixed results in the last week, but if you are a value investor, then yesterday was a big day. That’s when we revealed to our readers the fatal flaws of traditional value investing and the solution to this problem—our Top 10 Value Stocks strategy. Read on below to find out more about this 3-step process and its +38.63% annual returns…

:  |  News, Ratings, and Charts

3 Housing Market Stocks to Buy on the Dip

The housing market's strength is going to continue well into the next decade due to favorable supply and demand factors.

:  |  News, Ratings, and Charts

Finding Gems Amid the Market Wreckage

The S&P 500 (SPY) selloff has intensified this past week. So far, it’s looking and behaving like a culmination of the market’s rotation out of growth stocks. We’ve seen big declines in certain parts of the market from the big winners of 2020 that peaked in mid-February. Since their recent highs - the cannabis ETF (MJ) is down 44%; the cloud computing ETF (WCLD) is down 27%; and the semiconductor ETF (SMH) is down 14%. In today’s commentary, I cover some of the opportunities that have been created, ways to take advantage, and what I’m monitoring when it comes to the broad weakness in the market. Read on below to find out more…

:  |  News, Ratings, and Charts

3 Housing Market Stocks to Buy on the Dip

The housing market's strength is going to continue well into the next decade due to favorable supply and demand factors.

Read More Stories

More Aurora Cannabis Inc. (ACB) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ACB News